Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
In a review of data from the Nationwide Readmissions Database, researchers found that women with ovarian cancer classified as frail were at higher risk for need of intensive care, nonroutine discharge, and readmissions after surgery.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.